What drug did Absci design with AI, and what does it treat?

Absci designed ABS-201, an injectable antibody targeting the prolactin receptor. It is meant to treat both androgenetic alopecia (male or female pattern baldness) and endometriosis, and no approved existing injectable antibody currently treats either condition.

Why does Lilly think combining ABS-201 with a GLP-1 drug matters?

Lilly CEO Sean McClain suggested the idea of eventually fusing ABS-201 with a GLP-1 compound to create one shot for both hair regrowth and weight loss—what he called 'total vitality at an affordable price.' The strategy reflects Lilly's existing ambition to sell biologics through direct-to-consumer channels, similar to its LillyDirect initiative.

How does Absci plan to reduce drug development costs?

Absci's thesis is to use AI-designed drugs plus clinical trials run in China at a fraction of U.S. cost to compress the path from target to Phase 2 proof-of-concept from $150 million（約240億円） to $15–$20 million（約32億円）.

AI in HealthcareAI Stocks & MarketsFortune AIJul 1, 2026Jul 1, 2026, 19:00 JST

Eli Lilly backs AI drug startup Absci with $40M bet on injectable antibodies

Send on LINE

3 Key Points

What happened
Eli Lilly led a $100 million（約160億円） stock offering in Absci, an AI drug company, investing $40 million（約64億円） itself. Absci designed ABS-201, an injectable antibody targeting hair loss and endometriosis, using generative AI. The deal closed the same day Absci released positive Phase 1 safety data.
Why it matters
Lilly is betting that AI-designed drugs can succeed where traditional approaches haven't—no approved injectable antibody currently treats either condition ABS-201 targets. The deal signals confidence in Absci's strategy to use AI plus lower-cost clinical trials in China to compress development costs from $150 million（約240億円） to $15–$20 million（約32億円）, potentially reshaping drug economics.
What to watch
Absci's broader ambition is to eventually combine ABS-201 with a GLP-1 compound (used for weight loss) into a single shot. The injectable market is projected to be a $650 billion（約100兆円） opportunity in 2026, with GLP-1s alone projected to hit $190–$200 billion（約32兆円） by 2030. Whether ABS-201 becomes the first AI-designed antibody to prove efficacy in humans remains unknown.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Get news like this every morning, free

FAQ

What drug did Absci design with AI, and what does it treat?: Absci designed ABS-201, an injectable antibody targeting the prolactin receptor. It is meant to treat both androgenetic alopecia (male or female pattern baldness) and endometriosis, and no approved existing injectable antibody currently treats either condition.
Why does Lilly think combining ABS-201 with a GLP-1 drug matters?: Lilly CEO Sean McClain suggested the idea of eventually fusing ABS-201 with a GLP-1 compound to create one shot for both hair regrowth and weight loss—what he called 'total vitality at an affordable price.' The strategy reflects Lilly's existing ambition to sell biologics through direct-to-consumer channels, similar to its LillyDirect initiative.
How does Absci plan to reduce drug development costs?: Absci's thesis is to use AI-designed drugs plus clinical trials run in China at a fraction of U.S. cost to compress the path from target to Phase 2 proof-of-concept from $150 million（約240億円） to $15–$20 million（約32億円）.

Fortune AIRead Original Article

Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.